Lotus Eye Hospital and Institute LimitedLOTUSEYECorporate

Healthcare Latest results: Jun 2026 14 quarters of data

₹114.36

MCap ₹243 Cr · P/E n/m

Lotus Eye Hospital and Institute Limited — Stock analysis & AI research Lotus Eye Hospital and Institute Limited — Seasonality — best & worst months Lotus Eye Hospital and Institute Limited — Technical setup — score, trend, support & resistance Lotus Eye Hospital and Institute Limited — Live exchange announcements

🏭 Healthcare sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹17 Cr

Sales · Jun 2026

+26.2% YoY

₹3 Cr

Operating Profit · Jun 2026

+99.3% YoY

17.3%

OPM % · Jun 2026

+58.7% YoY

₹1 Cr

Net Profit · Jun 2026

+13.0% YoY

₹0.29

EPS · Jun 2026

+11.5% YoY

📝 Lotus Eye Hospital and Institute Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Lotus Eye Hospital and Institute Limited reported revenue of ₹17 crore for the quarter ended June 2026 (Q1 FY27), up 26.2% from ₹14 crore in the same quarter last year, and up 25.3% sequentially over the March 2026 quarter.

Net profit rose 13.0% year-on-year to ₹1 crore, from ₹1 crore. Earnings per share (EPS) came in at ₹0.29.

Operating profit stood at ₹3 crore — an operating margin (OPM) of 17.3%, compared with 10.9% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Lotus Eye Hospital and Institute Limited posted revenue of ₹54 crore, a growth of 8.4% over FY25, with a net profit of ₹0 crore (down 89.1% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹57 crore with a net profit of ₹0 crore.

Valuation snapshot

At the current price of ₹114.36, LOTUSEYE has a market capitalisation of ₹243 crore and a P/E that is not meaningful, because trailing profit is close to zero.

Within the Healthcare industry, it is the 15th-largest of the 22 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 40.14%, domestic institutional investors (DIIs) 0.02%, public shareholders 59.85% of Lotus Eye Hospital and Institute Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹243 Cr

Current Price ?

₹114.4

P/E ?

n/m

Industry P/E ?

34.70

P/B ?

4.04

P/S ?

4.25

P/FCF ?

-24.29

Enterprise Value ?

₹259 Cr

EV/EBITDA ?

53.31

PEG ?

N/A

Earnings Yield ?

0.1%

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

₹57 Cr

OPM ?

8.5%

Profit after tax (TTM) ?

₹0 Cr

EPS (TTM) ?

₹0.07

ROCE ?

1.2%

ROE ?

0.2%

ROA ?

0.2%

Growth

Sales — latest qtr ?

₹17 Cr

PAT — latest qtr ?

₹1 Cr

YoY qtr sales growth ?

26.2%

YoY qtr profit growth ?

13.0%

Sales growth (3y) ?

Sales growth (5y) ?

11%

Profit growth (3y) ?

-73%

Profit growth (5y) ?

-44%

Financial Health

Debt ?

₹16 Cr

Debt to Equity ?

0.26

Interest Coverage ?

-0.4

Current Ratio ?

N/A

Ownership

Promoter holding ?

40.14%

Change in promoter holding ?

-0.25%

Pledged percentage ?

N/A

Market

Return 3 months ?

-6.3%

Return 6 months ?

2.6%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	YoY %	QoQ %
Sales	11	13	13	12	11	13	13	12	12	14	13	14	14	17	+26.2%	+25.3%
Operating Profit	1	2	2	2	1	2	1	1	-0	1	1	1	0	3	+99.3%	+514.6%
Other Income	0	0	0	0	0	0	0	0	1	0	0	0	0	0	+10.5%	-55.3%
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	1	+325.0%	+54.5%
Depreciation	1	1	1	1	1	1	1	1	-1	1	1	1	1	2	+100.0%	+49.1%
Profit Before Tax	1	2	1	1	0	1	0	-0	1	1	0	-0	-0	1	+38.4%	+310.4%
Net Profit	1	1	1	1	0	1	0	-0	0	1	0	-0	-0	1	+13.0%	+290.6%
EPS	0.31	0.66	0.41	0.32	0.01	0.30	0.05	-0.12	0.12	0.26	0.06	-0.13	-0.15	0.29	+11.5%	+293.3%
OPM %	12.4%	19.0%	14.2%	13.1%	7.0%	12.9%	8.9%	6.4%	-1.5%	10.9%	5.9%	4.8%	3.5%	17.3%	+58.7%	+394.3%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	FY25	FY26	TTM	YoY %
Sales	₹50 Cr	₹54 Cr	₹57 Cr	+8.4%
Operating Profit	₹3 Cr	₹3 Cr	₹5 Cr	-1.3%
OPM %	6.92%	6.30%	8.48%	-9.0%
NPM %	1.47%	0.15%	0.26%	-89.8%
Other Income	₹1 Cr	₹1 Cr	₹1 Cr	-11.7%
Depreciation	₹3 Cr	₹4 Cr	₹5 Cr	+24.3%
Interest	₹0 Cr	₹1 Cr	₹1 Cr	+137.6%
EBIT	₹0 Cr	₹-0 Cr	₹0 Cr	-189.2%
PBT	₹1 Cr	₹-0 Cr	₹0 Cr	-104.0%
Tax	—	₹-0 Cr	₹-0 Cr	—
Net Profit	₹1 Cr	₹0 Cr	₹0 Cr	-89.1%
EPS	₹0.35	₹0.04	₹0.07	-88.6%
Material Cost	—	₹4 Cr	₹4 Cr	—
Employee Cost	—	₹3 Cr	₹3 Cr	—
Extraordinary Items	—	₹0 Cr	₹0 Cr	—

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	20.80	20.80	20.80	20.80	+0.0%
Reserves	36.78	38.61	39.20	39.34	+0.4%
Borrowings	0.67	1.11	3.43	15.83	+361.5%
Other Liabilities	4.93	6.11	6.14	6.63	+8.0%
Total Liabilities	63.18	66.63	69.57	82.60	+18.7%
Fixed Assets	44.18	48.65	54.07	65.81	+21.7%
CWIP	0.00	0.08	0.00	0.09	—
Investments	0.00	0.00	0.00	0.00	—
Other Assets	19.00	17.90	15.50	16.70	+7.7%
Total Assets	63.18	66.63	69.57	82.60	+18.7%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	4.39	5.68	2.70	3.02	+11.9%
Cash from Investing Activity	-2.19	-4.63	-6.13	-12.37	-101.8%
Cash from Financing Activity	-1.71	-3.40	-1.60	9.03	+664.4%
Net Cash Flow	0.49	-2.35	-5.03	-0.32	+93.6%
Free Cash Flow	1.30	0.10	-2.09	-10.01	-378.9%
CFO/OP	76%	101%	94%	99%	+5.3%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	9.08	9.54	9.72	8.22	-15.4%
Inventory Days	153.60	170.30	193.62	84.01	-56.6%
Days Payable	173.42	183.56	169.86	71.29	-58.0%
Cash Conversion Cycle	-10.74	-3.72	33.48	20.95	-37.4%
Working Capital Days	8.61	5.68	0.00	-12.23	—
ROCE %	10.25%	7.07%	2.99%	1.16%	-61.2%

👥 Shareholding (latest 5 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Sep 2026	% Chg
Promoters	40.39%	40.63%	40.66%	40.14%	40.14%	+0.0%
FIIs	0.01%	0.00%	0.01%	0.00%	—	—
DIIs	0.02%	0.02%	0.02%	0.02%	0.02%	+0.0%
Public	59.57%	59.33%	59.31%	59.85%	59.85%	+0.0%
No. of Shareholders	11,121	10,777	10,240	9,939	9,572	-3.7%

⚖️ Peer comparison

Industry: Healthcare · 22 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	VIJAYA Vijaya Diagnostic	₹1,507.80	15,530	82.7	857	187	42.3%	21.8%	19.5%	20.2%	22.8%	37.3%
2	METROPOLIS Metropolis Healthcare	₹596.30	12,370	61.1	1,710	203	24.7%	11.9%	23.6%	31.4%	16.6%	25.7%
3	HCG Healthcare Global	₹704.05	10,512	390.9	2,626	33	18.2%	1.3%	14.6%	-53.3%	13.1%	175.3%
4	YATHARTH Yatharth Hospital	₹988.90	9,528	54.1	1,200	171	23.6%	14.3%	36.2%	31.6%	47.6%	16.2%
5	JLHL Jupiter Life	₹277.85	9,109	9.7	1,557	187	22.1%	12.0%	20.9%	-6.7%	18.2%	-14.5%
6	THYROCARE Thyrocare Technologies	₹555.45	8,841	50.0	876	176	32.1%	20.1%	20.8%	79.4%	24.3%	33.2%
7	KOVAI Kovai Medical	₹6,260.50	6,850	26.7	1,644	256	27.9%	15.6%	15.7%	16.7%	15.3%	20.6%
8	INDRAMEDCO Indraprastha Medical	₹363.20	3,330	17.7	1,524	188	18.0%	12.4%	9.3%	13.7%	11.3%	9.5%
9	KRSNAA Krsnaa Diagnostics	₹543.40	1,763	18.1	816	98	26.8%	12.0%	7.8%	31.0%	22.1%	-19.3%
10	SURAKSHA Suraksha Diagnostic	₹311.85	1,624	45.3	325	35	31.4%	10.8%	23.1%	1.4%	20.7%	40.0%
11	SHALBY Shalby	₹132.15	1,418	38.0	1,176	37	12.1%	3.2%	5.0%	1683.0%	11.7%	36.7%
12	GPTHEALTH GPT Healthcare	₹157.90	1,296	27.4	491	48	18.5%	9.8%	15.1%	-21.9%	17.8%	62.5%
13	LAXMIDENTL Laxmi Dental	₹196.21	1,080	35.0	287	31	16.2%	10.9%	16.0%	-10.1%	13.2%	28.9%
14	NEPHROCARE Nephro Care	₹234.80	387	—	—	—	—	—	—	—	68.4%	347.7%
15	LOTUSEYE Lotus Eye	₹114.50	243	n/m	57	0	8.5%	0.3%	8.4%	-89.1%	26.2%	13.0%
16	UNIHEALTH Unihealth Hospitals	₹121.00	190	6.5	132	46	40.9%	34.8%	—	—	104.6%	71.5%
17	MADHAVBAUG Vaidya Sane	₹148.00	156	19.1	147	8	11.4%	5.6%	—	—	116.1%	94.3%
18	MHHL Mohini Health	₹57.05	104	—	145	-17	-1.4%	-11.7%	—	—	-6.6%	-1400.0%
19	MAITREYA Maitreya Medicare	₹120.65	82	—	45	-2	-1.0%	-5.5%	—	—	-5.2%	-1720.0%
20	AATMAJ Aatmaj Healthcare	₹26.75	60	83.6	24	1	9.7%	2.9%	—	—	22.5%	-39.4%
21	NIDAN Nidan Laborator.	₹33.00	46	30.6	26	2	19.0%	5.9%	—	—	-11.2%	-92.0%
22	ARTEMISMED Artemis Medicare	₹315.00	—	48.0	1,081	103	17.4%	9.6%	15.4%	25.9%	16.3%	30.9%

❓ Frequently asked questions

What was Lotus Eye Hospital and Institute Limited's revenue in Q1 FY27?

What was Lotus Eye Hospital and Institute Limited's net profit in Q1 FY27?